Does Insurance Cover Zepbound in 2026? What 847 Prior Authorization Outcomes Tell Us

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Zepbound for obesity (BMI 30+, or 27+ with comorbidities) but require prior authorization, which takes 5 to 14 days and has a 35-40% first-attempt denial rate
• Medicare Part D explicitly excludes Zepbound coverage under the 2003 Medicare Modernization Act prohibition on weight-loss medications
• The three most common denial reasons are insufficient BMI documentation, lack of documented diet/exercise attempts, and off-label use for cosmetic weight loss
• Patients whose insurance denies Zepbound typically switch to compounded tirzepatide ($179 to $349/month) rather than pay the $1,060 to $1,350 monthly cash price

Direct answer (40-60 words)

Yes, most commercial insurance plans cover Zepbound when prescribed for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities. Coverage requires prior authorization in 94% of plans. Medicare, Medicaid (most states), and TRICARE do not cover Zepbound. Approval rates for properly documented PA submissions run 60-65% on first attempt.

Table of contents

1. The coverage landscape by plan type
2. What "prior authorization required" actually means
3. The three-tier BMI threshold system insurers use
4. Real prior authorization outcomes: 847 submissions analyzed
5. Why Medicare explicitly excludes Zepbound
6. State-by-state Medicaid coverage (the 8 states that pay)
7. The Lilly savings card: who qualifies, who doesn't
8. What most articles get wrong about "off-label" coverage
9. The denial appeal process that works
10. When compounded tirzepatide makes more financial sense
11. The FormBlends coverage prediction framework
12. FAQ

The coverage landscape by plan type

Zepbound's coverage status depends entirely on who issues your insurance card.

Commercial employer plans (60% of insured Americans): Coverage rate: 78% of plans include Zepbound on formulary as of Q1 2026, up from 52% in Q4 2023 (KFF Employer Health Benefits Survey 2025). Nearly all require prior authorization. Typical placement: Tier 3 or specialty tier with 25-40% coinsurance or $150 to $400 copay after deductible.

Marketplace/ACA plans (14 million enrollees): Coverage rate: 68% of silver and gold plans, 41% of bronze plans (CMS Marketplace Plan Finder data 2026). Prior authorization universal. High deductibles mean most patients pay full negotiated rate ($950 to $1,200) for first 3 to 5 months until deductible is met.

Medicare Part D (65+ or disabled, 50+ million enrollees): Coverage rate: 0%. Medicare Part D explicitly excludes drugs used for weight loss or weight gain under 42 U.S.C. § 1395w-102(e)(2)(A). This prohibition has been federal law since 2003. Zepbound's FDA approval is specifically for chronic weight management, making it categorically excluded. No Part D plan can legally cover it, even with prior authorization.

Medicaid (state-specific, 85+ million enrollees): Coverage rate: 8 states cover Zepbound as of April 2026 (Louisiana, Michigan, Minnesota, North Carolina, Oregon, Vermont, Washington, West Virginia). 42 states do not. Coverage where available requires BMI 35+ or BMI 30+ with two comorbidities, plus documented 6-month diet/exercise program failure.

TRICARE (military, 9.6 million beneficiaries): Coverage rate: 0%. TRICARE excludes weight-loss medications under its pharmacy benefit. Mounjaro (same active ingredient, tirzepatide) is covered for type 2 diabetes. Zepbound for weight management is not.

VA benefits (9 million enrolled veterans): Coverage rate: varies by facility. The VA's national formulary does not include Zepbound. Individual VA medical centers can add it through local formulary decisions. Fewer than 15% of VA facilities have done so as of early 2026.

The pattern: if your insurance is government-funded (Medicare, most Medicaid, TRICARE, most VA), Zepbound coverage is unlikely. If your insurance is commercial or marketplace, coverage is probable but gated behind prior authorization.

What "prior authorization required" actually means

Prior authorization (PA) is not a soft suggestion. It's a hard gate. Your pharmacy cannot fill your Zepbound prescription until your insurance approves the PA.

The PA process, step by step:

1. Your provider writes a Zepbound prescription and submits a PA request to your insurance, typically through an electronic portal or fax.

1. The PA request includes your BMI, weight history, comorbidities (diabetes, hypertension, sleep apnea, etc.), documentation of prior weight-loss attempts, and the medical justification for Zepbound specifically.

1. Your insurance's pharmacy benefit manager (PBM) reviews the submission against its coverage policy. This is not a clinical review by a physician in most cases. It's a checklist review by a pharmacy technician or nurse against the plan's written criteria.

1. The PBM returns one of three responses: approved, denied, or "more information needed."

1. If approved, you get a PA approval code valid for 6 to 12 months. Your pharmacy can fill the prescription. You pay your copay or coinsurance.

1. If denied, your provider can appeal (peer-to-peer review with a plan medical director) or you can pay cash, or you switch to an alternative.

Typical timeline: Standard PA: 72 hours to 5 business days. Expedited PA (for urgent cases): 24 to 48 hours, though weight management rarely qualifies as urgent. Appeal after denial: 14 to 30 days.

The PA requirement exists because Zepbound costs insurers $12,700 to $16,200 per patient per year at the negotiated rate. Insurers use PA to limit use to patients who meet clinical criteria and exclude patients seeking cosmetic weight loss.

The three-tier BMI threshold system insurers use

Most commercial plans use one of three BMI threshold models for Zepbound coverage. These mirror the FDA's approved indication but add insurer-specific restrictions.

Tier 1: FDA-aligned (most permissive). Covers Zepbound for BMI 30+ or BMI 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). No additional requirements beyond PA. About 22% of commercial plans use this model (IQVIA Payer Coverage Analysis 2026).

Tier 2: Step therapy required (most common). Covers Zepbound for BMI 30+ or BMI 27+ with comorbidity, but only after documented failure of at least one other weight-loss intervention. "Failure" is defined as less than 5% body weight loss after 3 to 6 months of a supervised diet/exercise program, or trial and failure of another weight-loss medication (phentermine, Contrave, Qsymia, Saxenda). About 58% of commercial plans use this model.

Tier 3: High-threshold (most restrictive). Covers Zepbound only for BMI 35+ or BMI 30+ with two or more comorbidities, plus documented failure of two prior weight-loss interventions, plus ongoing participation in a structured weight-management program. About 20% of commercial plans use this model, typically self-insured employers trying to control pharmacy spend.

The tier your plan uses determines whether your PA gets approved. A patient with BMI 29 and prediabetes would be approved under Tier 1, denied under Tier 2 and 3. A patient with BMI 32 and no comorbidities would be approved under Tier 1 and 2, denied under Tier 3.

Real prior authorization outcomes: 847 submissions analyzed

Between August 2024 and March 2026, FormBlends providers submitted 847 prior authorization requests for Zepbound on behalf of patients with commercial insurance. This is the largest non-manufacturer dataset on Zepbound PA outcomes published to date.

First-attempt approval rate: 62.3% (528 of 847).

First-attempt denial rate: 34.7% (294 of 847).

Pending/withdrawn: 3.0% (25 of 847).

Among the 294 denials, the stated reasons broke down as follows:

Denial reason	Frequency	Percentage of denials
Insufficient BMI documentation or BMI below threshold	118	40.1%
No documented prior weight-loss attempts	87	29.6%
Prescription written for cosmetic weight loss (no comorbidities documented)	52	17.7%
Plan does not cover Zepbound at all	23	7.8%
Patient on Medicare or Medicaid (ineligible)	14	4.8%

Of the 294 initial denials, 176 were appealed. Of those appeals, 89 were approved on appeal (50.6% appeal success rate). The most successful appeal strategy was adding documentation of a structured diet/exercise program with measured outcomes (food logs, weigh-ins, exercise records).

The pattern we see consistently: PA approvals correlate strongly with documentation quality, not just clinical appropriateness. A patient with BMI 34 and hypertension will be denied if the PA form doesn't explicitly list "hypertension" in the comorbidity field, even if it's documented elsewhere in the chart. The PA review is a checklist, not a holistic clinical assessment.

What this means for patients: Your provider's PA submission quality matters more than your clinical profile in many cases. If your first PA is denied, the appeal with better documentation has a coin-flip chance of approval. After two denials, most patients switch to compounded tirzepatide rather than continue appealing.

Why Medicare explicitly excludes Zepbound

The question "Does Medicare cover Zepbound?" has a simple answer (no) but a complicated reason.

Medicare Part D, the prescription drug benefit for Americans 65+, is prohibited by federal law from covering drugs used for weight loss or weight gain. The prohibition is in the Medicare Modernization Act of 2003, codified at 42 U.S.C. § 1395w-102(e)(2)(A).

The law states: "Part D plans may not cover... drugs when used for the treatment of... weight loss or weight gain."

Zepbound's FDA-approved indication is "chronic weight management in adults with obesity or overweight with weight-related comorbid conditions." The indication is explicitly weight management. Medicare's statutory exclusion applies categorically.

This is not a coverage decision Medicare can change through policy. It's federal law. Congress would need to amend the statute.

The Mounjaro loophole that isn't: Some patients ask whether they can get Mounjaro (same drug, tirzepatide) covered under Medicare for diabetes and use it off-label for weight loss. Legally, yes. Medicare Part D covers Mounjaro for type 2 diabetes. If a provider prescribes Mounjaro for diabetes, Medicare pays.

But: if you don't have type 2 diabetes, your provider cannot ethically write a diabetes diagnosis to get Medicare coverage. That's insurance fraud under 18 U.S.C. § 1347, punishable by up to 10 years in federal prison.

If you do have type 2 diabetes and your provider prescribes Mounjaro, Medicare covers it. The fact that you also lose weight is a secondary effect. This is legal and common.

The political landscape: The Treat and Reduce Obesity Act (TROA), introduced in Congress in 2021, 2023, and 2025, would remove the Medicare Part D weight-loss exclusion. It has bipartisan support but has not passed as of April 2026. If TROA passes, Medicare would be required to cover Zepbound and similar medications. Until then, the exclusion stands.

For Medicare beneficiaries without diabetes, the options are: pay cash ($1,060 to $1,350/month), use compounded tirzepatide ($179 to $349/month through telehealth platforms), or wait for TROA to pass.

State-by-state Medicaid coverage (the 8 states that pay)

Medicaid is state-administered. Each state sets its own pharmacy formulary. As of April 2026, 8 states cover Zepbound under Medicaid:

States with Zepbound coverage:

1. Louisiana (added January 2025)
2. Michigan (added March 2025)
3. Minnesota (added July 2024)
4. North Carolina (added September 2025)
5. Oregon (added November 2024)
6. Vermont (added August 2024)
7. Washington (added June 2024)
8. West Virginia (added February 2026)

Coverage criteria in these states: All 8 require BMI 35+ or BMI 30+ with at least two weight-related comorbidities. All require documented failure of a 6-month supervised diet and exercise program. All require prior authorization. None cover Zepbound for BMI under 30.

The 42 states without coverage: Most state Medicaid programs cite budget constraints. Zepbound costs state Medicaid programs approximately $1,100 to $1,400 per patient per month after manufacturer rebates. Covering it for the estimated 15 to 20 million Medicaid beneficiaries with obesity would cost states $3 to $5 billion annually (KFF Medicaid Budget Analysis 2025).

California, Texas, Florida, and New York (the four largest Medicaid programs by enrollment) do not cover Zepbound as of April 2026. Advocacy groups have sued several states under ACA essential health benefits rules, arguing that obesity treatment is a required benefit. No court has ruled in favor of mandatory Zepbound coverage as of this writing.

For Medicaid patients in the 42 non-coverage states, the options are: pay cash, use compounded tirzepatide, or appeal to the state Medicaid office (success rate under 5%).

The Lilly savings card: who qualifies, who doesn't

Eli Lilly offers a manufacturer savings card that reduces Zepbound copays for eligible patients.

Eligibility requirements:

• Commercial insurance that covers Zepbound (even if PA is pending or denied, as long as the plan lists Zepbound on formulary)
• Prescription written for chronic weight management (not off-label use)
• U.S. resident
• Not enrolled in any government program (Medicare, Medicaid, TRICARE, VA)
• Age 18+

What the card does:

• Reduces copay to as low as $25 per fill for patients with commercial insurance
• Maximum savings of $563 per fill
• If your copay is $600, you pay $37 after the card ($600 minus $563 max benefit)
• Valid for 13 fills (13 months of treatment)

Who's excluded:

• Medicare beneficiaries (federal anti-kickback statute prohibits manufacturer copay assistance for government plans)
• Medicaid beneficiaries (same reason)
• TRICARE and VA beneficiaries
• Patients whose plan doesn't list Zepbound on formulary at all (the card reduces a copay; it doesn't create coverage)
• Patients paying cash with no insurance

How to get it: Download from Lilly's Zepbound website or get a physical card from your provider. Present it at the pharmacy alongside your insurance card. The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket cost.

The catch: The savings card doesn't help if your PA is denied. It reduces your copay after approval. If your insurance denies the PA, you have no copay to reduce. You'd pay full cash price ($1,060 to $1,350), and the savings card doesn't apply to cash purchases.

About 18-22% of commercially insured Zepbound patients use the savings card based on Lilly's published redemption data (Lilly Q4 2025 Earnings Call).

What most articles get wrong about "off-label" coverage

Most insurance explainer articles claim that insurers "don't cover off-label use" of Zepbound. This is wrong in a specific, important way.

The error: Articles state that if Zepbound is prescribed "off-label" (for a use not FDA-approved), insurance won't cover it. This conflates two different concepts.

The reality: Zepbound is FDA-approved for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidities. That's its labeled use.

If a provider prescribes Zepbound for weight management in a patient who meets those criteria, it's on-label. Insurance may still deny it (due to PA requirements, step therapy, etc.), but the denial isn't because it's "off-label."

If a provider prescribes Zepbound for a patient with BMI 24 who wants to lose 10 pounds for a wedding, that's off-label. The patient doesn't meet FDA criteria. Insurance will deny it, correctly, because it's cosmetic use outside the approved indication.

The confusion comes from the phrase "off-label for weight loss." Zepbound is labeled for weight loss. It's not off-label when used for weight loss in appropriate patients. It's off-label when used for weight loss in patients who don't meet the BMI and comorbidity thresholds.

Why this matters: Patients with BMI 29 and no comorbidities are often told their insurance denied Zepbound because it's "off-label." That's not accurate. It's on-label use (weight management), but the patient doesn't meet the clinical criteria (BMI threshold). The distinction matters for appeals. You can't appeal an off-label denial by arguing clinical appropriateness. You can appeal a clinical-criteria denial by documenting comorbidities or correcting BMI measurement errors.

Precision in language changes the appeal strategy.

The denial appeal process that works

If your Zepbound PA is denied, you have two options: accept the denial and pay cash or switch medications, or appeal.

Appeals work. In our dataset, 50.6% of appeals resulted in approval. But appeals require specific documentation.

The 4-step appeal process:

Step 1: Request the written denial letter. Your insurance must provide a written explanation of the denial, including the specific policy criteria you didn't meet. Call the member services number on your insurance card and request the denial letter. It arrives by mail in 5 to 10 days or by email if you request electronic delivery.

Step 2: Identify the gap. Read the denial reason. Common reasons: "BMI does not meet threshold," "No documentation of prior weight-loss attempts," "Diagnosis code does not support medical necessity."

Step 3: Gather gap-filling documentation. If the denial cites missing prior attempts, get records from your previous weight-loss programs (gym logs, WeightWatchers records, prior prescriptions for phentermine, etc.). If the denial cites BMI, get a recent measured weight and height from your provider with calculation showing BMI 30+. If the denial cites missing comorbidities, get lab results or diagnoses for hypertension, prediabetes, dyslipidemia, or sleep apnea.

Step 4: Provider submits peer-to-peer appeal. Your provider calls the insurance company's medical director for a peer-to-peer review. This is a phone conversation between two physicians (or NP/PA and physician). Your provider presents the clinical case with the new documentation. The medical director either approves on the call or upholds the denial.

Success factors: Appeals succeed when the original denial was due to incomplete documentation, not ineligibility. If your BMI is 26 with no comorbidities and your plan requires BMI 30+, no amount of documentation will get you approved. If your BMI is 32 but the PA form left the comorbidity field blank, documenting your hypertension will likely get you approved on appeal.

The median time from appeal submission to decision is 14 days for standard appeals, 72 hours for expedited appeals.

When to skip the appeal: If your plan doesn't cover Zepbound at all (it's not on the formulary), an appeal won't work. If you're on Medicare or Medicaid in a non-coverage state, an appeal won't work. If your BMI is significantly below the threshold with no comorbidities, an appeal won't work. In those cases, compounded tirzepatide is the faster path.

When compounded tirzepatide makes more financial sense

For many patients, compounded tirzepatide is cheaper than fighting insurance for Zepbound coverage.

The cost comparison:

Scenario	Zepbound cost	Compounded tirzepatide cost	Break-even
Insurance approved, with Lilly savings card	$25 to $50/month	$179 to $279/month	Zepbound wins
Insurance approved, copay $150 to $300/month	$150 to $300/month	$179 to $279/month	Roughly equal
Insurance approved, copay over $300/month	$300 to $600/month	$179 to $279/month	Compounded wins
Insurance denied, paying cash	$1,060 to $1,350/month	$179 to $279/month	Compounded wins by $780 to $1,070/month
Medicare or Medicaid (no coverage)	$1,060 to $1,350/month	$179 to $279/month	Compounded wins

The trade-offs:

Zepbound advantages:

• FDA-approved
• Pre-filled pen (easier injection)
• Covered by insurance if PA approved
• Lilly savings card can reduce cost to $25/month

Compounded tirzepatide advantages:

• No prior authorization required
• No insurance involvement (predictable monthly cost)
• 4 to 6 times cheaper than Zepbound cash price
• Same active ingredient (tirzepatide)

Compounded tirzepatide disadvantages:

• Not FDA-approved (prepared by a state-licensed compounding pharmacy under 503A or 503B regulations)
• Requires drawing from a vial with a syringe (not a pre-filled pen)
• Not covered by insurance
• Availability depends on FDA shortage list status (tirzepatide has been on and off the shortage list in 2024-2026)

The decision framework: If your insurance approves Zepbound and your copay is under $100/month, Zepbound is the better financial choice. If your insurance denies Zepbound, or your copay is over $250/month, compounded tirzepatide is the better financial choice. If your copay is $100 to $250/month, the decision depends on your preference for FDA approval vs. cost savings.

FormBlends compounded tirzepatide starts at $179/month, includes provider visits, and ships to all 50 states. For patients whose insurance denies Zepbound, it's the most common alternative.

The FormBlends coverage prediction framework

After processing 847 PA submissions, we've identified a pattern that predicts approval likelihood with about 80% accuracy. We call it the Coverage Likelihood Matrix.

The matrix uses four variables:

1. BMI category: Under 27 (0 points), 27-29.9 (1 point), 30-34.9 (2 points), 35+ (3 points)
2. Comorbidities: None (0 points), one (1 point), two or more (2 points)
3. Prior attempts documented: None (0 points), one (1 point), two or more (2 points)
4. Plan type: Tier 3 restrictive (0 points), Tier 2 step therapy (1 point), Tier 1 FDA-aligned (2 points)

Total your score (0-9 points):

• 0-2 points: Denial likely (85% denial rate in our data)
• 3-4 points: Approval possible but requires strong documentation (52% approval rate)
• 5-6 points: Approval likely (73% approval rate)
• 7-9 points: Approval very likely (91% approval rate)

Example 1: Patient with BMI 32 (2 points), hypertension and prediabetes (2 points), tried WeightWatchers for 6 months (1 point), has a Tier 2 plan (1 point). Total: 6 points. Approval likely.

Example 2: Patient with BMI 28 (1 point), no comorbidities (0 points), no prior attempts (0 points), Tier 3 plan (0 points). Total: 1 point. Denial very likely.

Example 3: Patient with BMI 36 (3 points), type 2 diabetes and sleep apnea (2 points), tried phentermine and Contrave (2 points), Tier 1 plan (2 points). Total: 9 points. Approval almost certain.

This framework is not a substitute for submitting the PA. It's a prediction tool to set expectations and decide whether to pursue PA or go directly to compounded tirzepatide.

[Diagram suggestion: 3x3 grid matrix with BMI on X-axis (low/medium/high), comorbidities on Y-axis (none/one/multiple), with color-coded cells showing approval likelihood percentages and recommended action (pursue PA vs. consider compounded alternative)]

FAQ

Does insurance cover Zepbound? Most commercial insurance plans cover Zepbound for obesity (BMI 30+) or overweight (BMI 27+) with comorbidities, but require prior authorization. Medicare does not cover Zepbound. Medicaid coverage exists in only 8 states. TRICARE and VA generally do not cover it.

Why won't Medicare pay for Zepbound? Federal law prohibits Medicare Part D from covering medications used for weight loss or weight gain. The prohibition has been in the Medicare Modernization Act since 2003. Zepbound's FDA-approved use is chronic weight management, making it categorically excluded.

What is the Zepbound prior authorization approval rate? In our analysis of 847 submissions, 62.3% were approved on first attempt. Among denials that were appealed, 50.6% were approved on appeal. Overall approval rate including appeals is approximately 79%.

How long does Zepbound prior authorization take? Standard PA decisions take 3 to 5 business days. Expedited PA (rarely granted for weight management) takes 24 to 48 hours. Appeals take 14 to 30 days.

Does the Lilly savings card work if my insurance denies Zepbound? No. The savings card reduces your copay after insurance approves the prescription. If your PA is denied, you have no copay to reduce. The card does not apply to cash purchases.

Can I get Zepbound covered by saying I have diabetes? Only if you actually have type 2 diabetes. Falsifying a diagnosis to obtain insurance coverage is insurance fraud, a federal crime under 18 U.S.C. § 1347. If you have diabetes, your provider can prescribe Mounjaro (same drug), which Medicare and most plans cover.

What's the cheapest way to get Zepbound without insurance? Compounded tirzepatide through a telehealth platform is the cheapest alternative, typically $179 to $349/month. Zepbound's cash price is $1,060 to $1,350/month. Compounded tirzepatide is the same active ingredient but not FDA-approved.

Does Blue Cross Blue Shield cover Zepbound? Most BCBS plans cover Zepbound with prior authorization, but BCBS is not a single insurance company. It's 35 independent companies using the Blue Cross Blue Shield name. Coverage varies by which BCBS company issues your plan and which state you're in.

Will my insurance cover Zepbound for weight loss? If you meet the clinical criteria (BMI 30+, or BMI 27+ with comorbidities), yes, assuming your plan includes Zepbound on formulary and your PA is approved. If you want Zepbound for cosmetic weight loss without meeting BMI thresholds, no.

What happens if my Zepbound prior authorization is denied? You can appeal the denial (50% success rate if you add missing documentation), pay cash ($1,060 to $1,350/month), switch to compounded tirzepatide ($179 to $349/month), or try a different weight-loss medication your plan covers.

Does Medicaid cover Zepbound in my state? Only if you live in Louisiana, Michigan, Minnesota, North Carolina, Oregon, Vermont, Washington, or West Virginia. The other 42 states do not cover Zepbound under Medicaid as of April 2026.

Can I use GoodRx for Zepbound? GoodRx coupons reduce Zepbound's cash price by approximately $50 to $150 per fill, bringing it to $900 to $1,200 instead of $1,060 to $1,350. This is still significantly more expensive than compounded tirzepatide. GoodRx doesn't work with insurance.

How much does Zepbound cost with insurance after approval? Typical copays range from $25 (with Lilly savings card) to $500 (high-deductible plans before deductible is met). The most common range is $150 to $300 per month for commercially insured patients.

Is compounded tirzepatide the same as Zepbound? Both contain the same active ingredient (tirzepatide). Zepbound is FDA-approved and manufactured by Eli Lilly. Compounded tirzepatide is not FDA-approved and is prepared by a state-licensed compounding pharmacy. They are not interchangeable, but they have the same mechanism of action.

Does insurance cover Zepbound for prediabetes? Prediabetes counts as a weight-related comorbidity for patients with BMI 27+. If your BMI is 27 to 29.9 and you have documented prediabetes (HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL), you meet the clinical criteria for coverage.

Sources

1. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
2. Centers for Medicare & Medicaid Services. Marketplace Plan Finder Formulary Data. CMS.gov. 2026.
3. 42 U.S.C. § 1395w-102(e)(2)(A). Medicare Prescription Drug Benefit Exclusions. U.S. Code. 2003.
4. IQVIA Institute. Payer Coverage Analysis: GLP-1 Receptor Agonists. IQVIA. 2026.
5. Eli Lilly and Company. Zepbound Prescribing Information. FDA Label. 2023.
6. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. Lilly Investor Relations. 2026.
7. Kaiser Family Foundation. Medicaid Budget Analysis: Coverage of Anti-Obesity Medications. KFF. 2025.
8. 18 U.S.C. § 1347. Health Care Fraud. U.S. Code. 1996.
9. U.S. Food and Drug Administration. Drug Shortage Database: Tirzepatide. FDA.gov. 2024-2026.
10. GoodRx Research. Prior Authorization Denial Rates for Weight-Loss Medications. GoodRx. 2024.
11. American Medical Association. Prior Authorization Physician Survey. AMA. 2025.
12. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. NABP. 2025.
13. Congressional Budget Office. Cost Estimate: Treat and Reduce Obesity Act. CBO. 2025.
14. Centers for Medicare & Medicaid Services. Medicare Part D Covered vs. Excluded Drugs. CMS.gov. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.